WO2014097137A2 - Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques - Google Patents

Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques Download PDF

Info

Publication number
WO2014097137A2
WO2014097137A2 PCT/IB2013/061023 IB2013061023W WO2014097137A2 WO 2014097137 A2 WO2014097137 A2 WO 2014097137A2 IB 2013061023 W IB2013061023 W IB 2013061023W WO 2014097137 A2 WO2014097137 A2 WO 2014097137A2
Authority
WO
WIPO (PCT)
Prior art keywords
independently
administration
formula
compositions
pharmaceutical composition
Prior art date
Application number
PCT/IB2013/061023
Other languages
English (en)
Other versions
WO2014097137A3 (fr
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014097137A2 publication Critical patent/WO2014097137A2/fr
Publication of WO2014097137A3 publication Critical patent/WO2014097137A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Definitions

  • kits comprising any of the pharmaceutical compositions disclosed herein.
  • the kit may comprise instructions for use in the treatment of seizures and neurologic diseases or its related complications.
  • isomers Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Diastereomers are stereoisomers with opposite configuration at one or more chiral centers which are not enantiomers. Stereoisomers bearing one or more asymmetric centers that are non- superimposable mirror images of each other are termed "enantiomers.” When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible.
  • metabolic condition refers to an Inborn errors of metabolism (or genetic metabolic conditions) are genetic disorders that result from a defect in one or more metabolic pathways; specifically, the function of an enzyme is affected and is either deficient or completely absent.
  • materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)
  • Extended release formulations are generally prepared as diffusion or osmotic systems, for example, as described in "Remington— The Science and Practice of Pharmacy", 20th. Ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000).
  • a diffusion system typically consists of one of two types of devices, reservoir and matrix, which are wellknown and described in die art.
  • the matrix devices are generally prepared by compressing the drug with a slowly dissolving polymer carrier into a tablet form.
  • a pulsed release dosage form is one that mimics a multiple dosing profile without repeated dosing and typically allows at least a twofold reduction in dosing frequency as compared to the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing, conventional solid dosage form).
  • a pulsed release profile is characterized by a time period of no release (lag time) or reduced release followed by rapid drug release.
  • Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of a subject composition which may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated, and the particular mode of administration.
  • Methods of preparing these formulations or compositions include the step of bringing into association subject compositions with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a subject composition with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Suspensions in addition to the subject compositions, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
  • the ointments, pastes, creams and gels may contain, in addition to subject compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of such substances.
  • Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • Transdermal patches may be passive or active. Passive transdermal drug delivery systems currently available, such as the nicotine, estrogen and nitroglycerine patches, deliver small-molecule drugs. Many of the newly developed proteins and peptide drugs are too large to be delivered through passive transdermal patches and may be delivered using technology such as electrical assist (iontophoresis) for large-molecule drugs.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne des composés de formule I et de formule II ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, solvates, énantiomères, stéréoisomères et hydrates. Les compositions pharmaceutiques comprenant une quantité efficace des composés de formule I et de formule II, et les méthodes destinées à traiter les AVC et les maladies neurologiques selon l'invention peuvent être formulées pour une administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, sous la forme d'un sirop, ou d'une injection. Ces compositions peuvent être utilisées pour traiter les crises épileptiques, l'épilepsie, les AVC simples et complexes.
PCT/IB2013/061023 2012-12-18 2013-12-17 Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques WO2014097137A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5281CH2012 2012-12-18
IN5281/CHE/2012 2012-12-18

Publications (2)

Publication Number Publication Date
WO2014097137A2 true WO2014097137A2 (fr) 2014-06-26
WO2014097137A3 WO2014097137A3 (fr) 2017-03-23

Family

ID=50979337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061023 WO2014097137A2 (fr) 2012-12-18 2013-12-17 Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques

Country Status (1)

Country Link
WO (1) WO2014097137A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046835A1 (fr) * 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
WO2022045824A1 (fr) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Composés carbamate de phényle alkyle destinés à être utilisés dans la prévention ou le traitement d'une maladie neurodégénérative
US11896593B2 (en) 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2089002A1 (fr) * 2006-10-13 2009-08-19 Janssen Pharmaceutica, N.V. Compositions de phénylalkylcarbamate
US20090105498A1 (en) * 2007-10-18 2009-04-23 Porstmann Frank Improved process for preparing 2-(substituted phenyol)-2-hydroxy-ethyl-carbamates
EP2487152A1 (fr) * 2010-11-17 2012-08-15 UCB Pharma GmbH Procédé pour la préparation de Lacosamide avec la résolution de la O-methyl-DL-Sérine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046835A1 (fr) * 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions et méthodes de traitement de l'épilepsie et de troubles neurologiques
WO2022045824A1 (fr) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Composés carbamate de phényle alkyle destinés à être utilisés dans la prévention ou le traitement d'une maladie neurodégénérative
US11931332B2 (en) 2020-08-31 2024-03-19 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US11896593B2 (en) 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Also Published As

Publication number Publication date
WO2014097137A3 (fr) 2017-03-23

Similar Documents

Publication Publication Date Title
US9434704B2 (en) Compositions and methods for the treatment of neurological degenerative disorders
WO2014087367A2 (fr) Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
US9492409B2 (en) Compositions and methods for the treatment of local pain
WO2014115098A1 (fr) Compositions et procédés pour le traitement de maladies neurologiques et d'une inflammation
US9403793B2 (en) Compositions and methods for the treatment of moderate to severe pain
US9580383B2 (en) Compositions and methods for the treatment of multiple sclerosis
US9499526B2 (en) Compositions and methods for the treatment of neurologic diseases
WO2014097137A2 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
AU2013285126A1 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014195850A2 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014068506A2 (fr) Compositions et procédés pour le traitement de maladies autoimmunes
US20150141500A1 (en) Compositions and methods for the treatment of neurological diseases
AU2013257707A1 (en) Compositions and methods for the treatment of epilepsy
US20170129870A1 (en) Compositions and methods for the treatment of neurological diseases
WO2014068459A2 (fr) Compositions et méthodes de traitement de la douleur et de maladies neurologiques
WO2014057439A2 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
WO2015028976A2 (fr) Composés et méthodes de traitement de maladies inflammatoires
WO2014068461A2 (fr) Compositions et méthodes de traitement d'une inflammation aiguë
US9315461B2 (en) Compositions and methods for the treatment of neurologic diseases
WO2014203198A2 (fr) Compositions et procédés de traitement de maladies neurologiques et de complications rénales
WO2013179153A1 (fr) Compositions et méthodes de traitement de troubles neurologiques dégénératifs et de maladies neurologiques
US9290486B1 (en) Compositions and methods for the treatment of epilepsy
US9303038B2 (en) Compositions and methods for the treatment of epilepsy and neurological diseases
WO2014087331A2 (fr) Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques
US9266823B2 (en) Compositions and methods for the treatment of parkinson's disease

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13865155

Country of ref document: EP

Kind code of ref document: A2